The pipeline
Argenx, an immunology biotech founded in Ghent in 2008, is now Belgium's most valuable biotech company, trading on both Nasdaq and Euronext — a scale of outcome that is genuinely rare for a European biotech spin-out.
It did not appear from nowhere: Ghent University and VIB, the Flanders life-sciences research institute, have spun out multiple biotech companies from the same city, including Biotalys and Aphea.Bio, making Argenx one success in a genuine pipeline rather than an isolated outlier.
What that produces locally
A research-to-company pathway that is unusually well-developed for a city Ghent's size — strong university science, dedicated institutional support, and a track record of at least one outcome large enough to be internationally recognised.
Underneath that runs an ordinary, attractive Flemish university city: canals, a historic centre, and a business community serving students, tourists and the wider region.
The buyer
The biotech-adjacent layer is specialist, well-funded and internationally staffed. The wider city is Dutch-speaking (Flemish), moderate in pace, and conventional in how it buys — reputation and personal relationships carry real weight.
The practical read
If you're near the university-biotech pipeline, expect sophistication and international staff. For the town itself, Dutch and a straightforward, unhurried approach serve better than an aggressive sales pitch.
Sources
Caveats and sourcing
- Verifiable — Argenx's Ghent founding, founding year and listing status, and the named university/VIB spin-outs.
- Characterising claims — the description of the wider city and buyer behaviour is interpretation.